Categories: CancerNews

From the Margins: Gilead’s Book Uniquely Captures What It’s Like To Be Marginalized by Disease

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

NORTHAMPTON, MA / ACCESSWIRE / January 30, 2024 / Gilead Sciences – The personal journeys of six people in the United Kingdom living with HIV, hepatitis C and cancer – and the challenges they face due to stigma and health inequities – come together in the form of a new, intentionally difficult-to-read book from Gilead. Entitled “From the Margins,” each person’s experience is deliberately written around the margins of the book in order to raise awareness of what it feels like to live on the periphery of society with a chronic or life-threatening disease.

“I had one foot in my cancer patient space and the other in my LGBTQ+ space,” reads an excerpt from one of the participants, named Stewart. “But there was no space where I could talk about both those things and bring them close to each other.”

Gilead teamed up with David Olusoga, a British historian and professor, to put the book together. “Throughout history and to this day, there are many people pushed to the margins of society where illness intertwines with social class, race, ethnicity, sexuality and poverty,” he says. “They shouldn’t have to take it upon themselves to overcome societies prejudices and inequalities.”

The book was published last September, and its unique format and important messages have earned significant media coverage and interest among the global patient and medical community.

The work is part of Gilead’s larger efforts to spotlight and address stigma, discrimination and other barriers to wellbeing and care; and ultimately, to improve health equity.

To read From the Margins, download a copy here.

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences

View the original press release on accesswire.com

Staff

Recent Posts

Proper Good, Inc. Successfully Secures New Funding to Fuel Growth

AUSTIN, Texas, Jan. 13, 2025 /PRNewswire/ --  Proper Good, Inc., a leader in ready-to-eat meal solutions,…

2 hours ago

Ex-Deep Genomics, Moderna Execs Get Backing Led by Gradient to Develop Next-Generation mRNA Therapeutics with AI

SAN FRANCISCO, Jan. 13, 2025 /PRNewswire/ -- Kerna Laboratories Inc, a San Francisco-based AI biotech startup,…

2 hours ago

Ventra Health Appoints Sarah Herzog President of Radiology as ADVOCATE RCM Integration is Completed

Former ADVOCATE RCM Head of Operations to Lead Radiology Business Unit Focused on Optimizing Performance…

2 hours ago

Human Longevity, Inc. and SleepScore Labs Partner to Launch AI Driven Personalized Precision Sleep Program

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Human Longevity, Inc. (HLI) and SleepScore…

2 hours ago

EDETEK Unveils Revolutionary Life Sciences R&D Cloud for Clinical Development

Unveiling the next generation paradigm in Clinical Data Sciences PRINCETON, N.J., Jan. 13, 2025 /PRNewswire/…

2 hours ago

Vevo Therapeutics to Open Source Milestone Tahoe-100M Dataset

Tahoe-100M is the world's largest single-cell atlas of how drug molecules impact biology of patient…

2 hours ago